1 December 2019 - The December 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The December issue of the Schedule includes several new & revised listings:

• Amino acid formula with vitamins and minerals, low in phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid (PKU Explore 5, PKU Explore 10) - new formulation
• Benralizumab (Fasenra) - restriction change
• Blinatumomab (Blincyto) - new indication
• Carmellose sodium (Evolve Carmellose) - new formulation
• Clostridium botulinum toxin type A (Dysport) - new indication
• Dolutegravir sodium with lamivudine (Dovato) - new combination product
• Glycomacropeptide with docosahexaenoic acid and low in phenylalanine (PKU GMPro LQ) - new combination product
• Hypromellose sodium (Evolve Hypromellose) - new formulation
• Mepolizumab (Nucala) - restriction change
• Omalizumab (Xolair) - restriction change
• Pembrolizumab (Keytruda) - new indication
• Risakizumab (Skyrizi) - new medicine
• Sevelamer carbonate (Sevelamer Apotex) - new formulation
• Sodium phenylbutyrate (Pheburane) - new medicine
• Tezacaftor with ivacaftor (Symdeko) - new combination product
• Trastuzumab (Kanjinti) - new biosimilar medicine

Read Summary of PBS Changes